Bayer and Google Cloud to develop AI solutions for radiologists

Bayer has entered into a strategic partnership with Google Cloud aimed at accelerating the development of AI-driven solutions tailored for radiologists. This collaboration leverages Google Cloud's cutting-edge technology, including its powerful generative AI tools, to address the pressing challenges faced by healthcare professionals while ensuring patient benefit. 

By focusing on scalability and compliance in creating AI medical imaging software products, the companies aim to enhance the efficiency and security of managing critical medical imaging data, which constitutes a significant portion of healthcare data worldwide. Through Bayer's innovation platform, built on Google Cloud infrastructure, a cloud-native pipeline is established to streamline the journey from conceptualising product ideas to their successful launch. This platform offers robust capabilities for data analysis, experimentation with AI-powered solutions, and access to a comprehensive data ecosystem, facilitating the development and validation of regulatory-compliant solutions. 

Upon its release, the platform will enable life science and healthcare companies to seamlessly integrate AI medical solutions into existing healthcare systems, with provisions for continuous monitoring and improvement based on field data insights. Leveraging tools such as BigQuery, Vertex AI, Healthcare API, and Chronicle, this platform aims to introduce new medical imaging tools rapidly and cost-effectively into the market. The initial version of the platform is slated for extended testing in the EU and the US in 2024. 

This partnership builds upon the longstanding collaboration between Bayer and Google Cloud, which has previously focused on expediting drug discovery and supporting patient diagnosis. Bayer Radiology president Nelson Ambrogio expressed confidence in the collaboration's ability to transform vast amounts of data into valuable insights, ultimately benefiting both radiologists and patients alike. 

In a notable development, Bayer's non-small cell lung cancer (NSCLC) candidate, BAY 2927088, received breakthrough device designation from the US Food and Drug Administration in February 2024.

Click here to read the original news story.